GH Research PLC Company Profile
NASDAQ: GHRSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
GH Research at a glance
GH Research PLC (NASDAQ: GHRS) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Dublin, Ireland. GH Research is led by Dr. Velichka Valcheva M.D., M.Sc. and employs about 73 people. The company's shares have traded publicly since 2021.
At a market capitalization of $1.40 billion, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001855129, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does GH Research do?
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Business description based on the company's public filings.
Company information
- Legal name
- GH Research PLC
- Ticker
- NASDAQ: GHRS
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Velichka Valcheva M.D., M.Sc.
- Employees
- 73
- Headquarters
- Joshua Dawson House, Dublin, Ireland
- Phone
- 353 1 437 8334
- Website
- ghres.com
- IPO year
- 2021
- Market cap
- $1.40B
- SEC CIK
- 0001855129
Companies similar to GH Research
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NKTRNektar Therapeutics | 40.80 | +1.34% | $1.39B | vs GHRS |
| OMEROmeros Corporation | 19.12 | +1.97% | $1.38B | vs GHRS |
| ANABAnaptysBio Inc. | 46.21 | +1.23% | $1.38B | vs GHRS |
| RAPPRapport Therapeutics Inc. | 29.85 | -3.27% | $1.43B | vs GHRS |
| TYRATyra Biosciences Inc. | 19.97 | -2.06% | $1.37B | vs GHRS |
| AAPGAscentage Pharma Group International American Depository Shares | 14.55 | -4.09% | $1.36B | vs GHRS |
| PCRXPacira BioSciences Inc. | 36.39 | +44.40% | $1.45B | vs GHRS |
| KARDKardigan Inc. | 14.20 | +2.68% | $1.33B | vs GHRS |